Clinical Trials

Prostatic Neoplasms

NCT03866382 2026-05-26

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

314 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT04346225 2026-05-19

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

75 enrolled

Prostatic Neoplasms

NCT03933670 2026-05-18

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

60 enrolled

Prostatic Neoplasms

NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

804 enrolled

Prostatic Neoplasms

NCT06305598 2026-05-15

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

14 enrolled

Prostatic Neoplasms

NCT06733350 2026-05-14

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Phase 4 Recruiting

600 enrolled

Prostatic Neoplasms

NCT04071236 2026-05-13

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

90 enrolled

Lymphatic Metastasis, Prostatic Neoplasms

NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

BreastGastrointestinalGenitourinaryGynecologic

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT06632977 2026-05-08

PREDICT

474 enrolled

Prostatic Neoplasms

NCT06931340 2026-05-08

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

1,260 enrolled

Prostatic Neoplasms

NCT04134260 2026-05-07

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

586 enrolled

Prostatic Neoplasms

NCT05946213 2026-05-07

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

1,209 enrolled

Phase EARLY_PHASE1 Recruiting

Prostatic Neoplasms

NCT02526368 2026-04-30

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

80 enrolled

Prostatic Neoplasms

NCT05710380 2026-04-27

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

180 enrolled

Prostatic Neoplasms

NCT06378866 2026-04-20

DIVINE

532 enrolled

Prostatic Neoplasms

NCT07219147 2026-04-20

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

NCT06389786 2026-04-06

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

50 enrolled

Prostatic Neoplasms

NCT06325046 2026-03-31

Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer

144 enrolled

Prostatic Neoplasms

NCT06526299 2026-03-24

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

51 enrolled

Prostatic Neoplasms

NCT07145177 2026-03-23

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Prostatic Neoplasms

NCT05888532 2026-03-17

64Cu-GRIP B in Patients With Advanced Malignancies

91 enrolled

Kidney Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Lipodystrophy, Congenital Generalized

NCT06288113 2026-03-13

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

40 enrolled

Prostatic Neoplasms

NCT07025369 2026-03-13

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Prostatic Neoplasms

NCT06216249 2026-03-10

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

90 enrolled

Phase EARLY_PHASE1 Recruiting

Prostatic Neoplasms

NCT07164027 2026-03-10

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

Prostatic Neoplasms

NCT06330805 2026-03-09

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

70 enrolled

Prostatic Neoplasms

NCT06675357 2026-03-04

Using FAPI PET/MRI to Evaluate Prostate Cancer

Prostatic Neoplasms

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

48 enrolled

Prostatic Neoplasms

NCT06625034 2026-02-10

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

108 enrolled

Prostatic Neoplasms

NCT07276438 2026-02-05

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

186 enrolled

Prostatic Neoplasms

NCT06636526 2026-02-04

The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study).

Recruiting

1,000 enrolled

Genetic Risk Score, Prostatic Neoplasms, Genetic Predisposition to Disease

NCT05806515 2026-01-29

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

44 enrolled

Prostatic Neoplasms

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

60 enrolled

Prostatic Neoplasms

NCT06145633 2026-01-28

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

15 enrolled

Prostatic Neoplasms

NCT06470243 2026-01-22

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

528 enrolled

Prostatic Neoplasms

NCT06205316 2026-01-20

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

118 enrolled

Prostatic Neoplasms

NCT06039371 2026-01-14

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

69 enrolled

Prostatic Neoplasms

NCT06384222 2025-12-30

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

32 enrolled

Prostatic Neoplasms

NCT06788886 2025-12-30

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

CNSEndocrineGenitourinaryNET

147 enrolled

Brain Neoplasms, Multiple Sclerosis, Prostatic Neoplasms, Neuroendocrine Tumors

NCT05097274 2025-12-16

GENPET

Recruiting

50 enrolled

Prostatic Neoplasms

NCT06995053 2025-11-10

ILLUSION

80 enrolled

Prostatic Neoplasms

NCT07185165 2025-11-10

ECLIPSE

81 enrolled

Prostatic Neoplasms

NCT06200103 2025-09-11

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

236 enrolled

Prostatic Neoplasms

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers